Alterity Therapeutics (ATHE) Equity Average (2009 - 2025)

Alterity Therapeutics' Equity Average history runs 12 years deep, the most recent figure standing at $3.5 billion for Q4 2025.

• In Q4 2025, Equity Average rose 109.57% year-over-year to $3.5 billion; the TTM figure through Dec 2025 stood at $3.5 billion (up 109.57% YoY), while the FY2023 annual figure was $20.3 million, down 16.81% from the prior year.
• Equity Average was $3.5 billion for Q4 2025 at Alterity Therapeutics, up from $1.7 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $3.5 billion in Q4 2025 to a low of $754.0 million in Q2 2021.
• Historically, Equity Average has averaged $1.4 billion across 5 years, with a median of $880.7 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Equity Average increased 5.01% in 2024, then jumped 109.57% in 2025.
• A 5-year view of Equity Average shows it stood at $754.0 million in 2021, then gained by 6.97% to $806.5 million in 2022, then rose by 14.04% to $919.8 million in 2023, then surged by 81.46% to $1.7 billion in 2024, then surged by 109.57% to $3.5 billion in 2025.
• The last three Equity Average figures came in at $3.5 billion (Q4 2025), $1.7 billion (Q2 2025), and $1.7 billion (Q4 2024), per Business Quant data.